4/7/2024

Epoetin Alfa Injection

Products Affected - Description

- Retacrit solution for injection, Pfizer, 2,000 unit/mL, 1 mL single dose vial, 10 count, NDC 00069-1305-10
- Retacrit solution for injection, Pfizer, 20,000 unit/2 mL, 1 mL multiple dose vial, 10 count, NDC 00069-1318-10
- Retacrit solution for injection, Pfizer, 20,000 unit/mL, 1 mL multiple dose vial, 10 count, NDC 00069-1311-10
- Retacrit solution for injection, Pfizer, 3,000 unit/mL, 1 mL single dose vial, 10 count, NDC 00069-1306-10
- Retacrit solution for injection, Pfizer, 4,000 unit/mL, 1 mL single dose vial, 10 count, NDC 00069-1307-10

Reason for the Shortage

- Amgen has Epogen available.
- Janssen has Procrit available.
- Pfizer states the reason for the shortage is manufacturing delay.

Available Products

- Epogen solution for injection, Amgen, 10,000 unit/mL, 1 mL single dose vial, 10 count, NDC 55513-0144-10
- Epogen solution for injection, Amgen, 2,000 unit/mL, 1 mL single dose vial, 10 count, NDC 55513-0126-10
- Epogen solution for injection, Amgen, 20,000 unit/2 mL, 2 mL multiple dose vial, 10 count, NDC 55513-0283-10
- Epogen solution for injection, Amgen, 20,000 unit/mL, 1 mL multiple dose vial, 10 count, NDC 55513-0478-10
- Epogen solution for injection, Amgen, 3,000 unit/mL, 1 mL single dose vial, 10 count, NDC 55513-0267-10
- Epogen solution for injection, Amgen, 4,000 unit/mL, 1 mL single dose vial, 10 count, NDC 55513-0148-10
- Procrit solution for injection, Janssen, 10,000 unit/mL, 1 mL single dose vial, 6 count, NDC 59676-0310-01
- Procrit solution for injection, Janssen, 10,000 unit/mL, 1 mL single dose vial, 25 count, NDC 59676-0310-02
- Procrit solution for injection, Janssen, 2,000 unit/mL, 1 mL single dose vial, 6 count, NDC 59676-0302-01
- Procrit solution for injection, Janssen, 20,000 unit/2 mL, 2 mL multiple dose vial, 4 count, NDC 59676-0312-04
- Procrit solution for injection, Janssen, 20,000 unit/mL, 1 mL multiple dose vial, 4 count, NDC 59676-0320-04
- Procrit solution for injection, Janssen, 3,000 unit/mL, 1 mL single dose vial, 6 count, NDC 59676-0303-01
- Procrit solution for injection, Janssen, 4,000 unit/mL, 1 mL single dose vial, 6 count, NDC 59676-0304-01
- Procrit solution for injection, Janssen, 40,000 unit/mL, 1 mL single dose vial, 4 count, NDC 59676-0340-01
- Retacrit solution for injection, Pfizer, 10,000 unit/mL, 1 mL single dose vial, 10 count, NDC 00069-1308-10
- Retacrit solution for injection, Pfizer, 40,000 unit/mL, 1 mL single dose vial, 4 count, NDC 00069-1309-04

Estimated Resupply Dates

- Pfizer has Retacrit 2,000 units/mL 1 mL vials, 3,000 units/mL 1 mL vials, and 4,000 units/mL 1 mL vials on back order and the company estimates a release date of June 2024. The 20,000 units/mL 1 mL vials are on back order and the company estimates a release date of April 2024. The 20,000 units/2 mL 1 mL vials are on back order and the company cannot estimate a release date.

Updated

Updated April 7, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 27, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.